Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Uscom (UCM) has signed a supply and development agreement with A&D Japan for the Uscom BP+ blood pressure monitor
  • This agreement covers the installation of new technology into Uscom’s device as it approaches regulatory approval in China and the United States
  • According to Uscom, BP+ provides a highly accurate and repeatable measurement of central blood pressure and pulse pressure waveforms, which take be used on both the arm and the heart
  • The company says its device performs better than current tech used to manage hypertension, one of the leading causes of premature death in the world
  • Uscom shares are down a slight 4.35 per cent and are trading for 22 cents each

Uscom (UCM) has signed a supply and development agreement with A&D Japan for the Uscom BP+ blood pressure monitor.

A&D (Analogue and Digital) are a Tokyo-based company that is engaged in the development, manufacture, and sale of measurement instruments in the medical and healthcare sector.

This agreement covers the installation of new technology from A&D in Uscom’s device as it approaches regulatory approval in China and the United States.

Uscom BP+ is a highly-accurate blood pressure monitor that can measure blood pressure waveforms in not only the arm but the heart.

It provides a highly accurate and repeatable measurement of central blood pressure and pulse pressure waveforms.

According to Uscom, BP+ is set to replace traditional blood pressure monitors and is the up-and-coming standard of care measurements for hypertension, heart failure, and general heart health.

“Current hypertensive management is poor, and we have developed the BP+ to advance the science in this common and dangerous condition,” Executive Chairman Associate Professor Rob Phillips stated.

“Quality technology is critical for our devices, and this new partnership with A&D allows Uscom to provide clinicians with the best tools for BP monitoring and hypertensive care,” he said.

Hypertension

According to the World Health Organisation (WHO), hypertension is one of the leading causes of premature death in the world.

It has estimated that of the 1.13 billion people who have it, only one in five has it under control.

WHO hopes to reduce the prevalence of hypertension by 25 per cent by 2025.

Hypertension, also known as high blood pressure, is a condition in which the force of the blood against the artery walls in the body is too high.

While hypertension typically has no symptoms, if it’s left untreated for a long period of time it can cause health conditions such as a stroke or heart disease.

Treatments include a healthier diet with less salt, quitting smoking, regular exercise, and medication.

Uscom shares are down a slight 4.35 per cent and are trading for 22 cents each at 1:49 pm AEST.

UCM by the numbers
More From The Market Herald
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.